Novavax (NASDAQ:NVAX) Price Target Raised to $9.00

Novavax (NASDAQ:NVAX) had its price objective hoisted by TD Cowen from $8.00 to $9.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on NVAX. Weiss Ratings raised shares of Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. Jefferies Financial Group restated a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. BTIG Research reiterated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research report on Tuesday, January 20th. Finally, HC Wainwright lifted their price objective on Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.13.

Novavax Stock Performance

Shares of NVAX stock opened at $10.11 on Wednesday. The stock has a fifty day moving average price of $9.05 and a 200 day moving average price of $8.20. The stock has a market cap of $1.66 billion, a PE ratio of -17.43 and a beta of 2.37. Novavax has a 1 year low of $5.80 and a 1 year high of $11.97.

Novavax (NASDAQ:NVAX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The company had revenue of $118.90 million for the quarter, compared to analyst estimates of $79.81 million. During the same quarter in the prior year, the company earned $2.93 earnings per share. Novavax’s revenue was down 79.0% compared to the same quarter last year. As a group, equities research analysts predict that Novavax will post -0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Novavax by 95.2% during the 1st quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Novavax by 2.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 2,750 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of Novavax during the first quarter valued at approximately $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Novavax by 16.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock worth $2,005,000 after acquiring an additional 44,105 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Novavax during the first quarter worth approximately $167,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax’s first-quarter results beat expectations, helping fuel a sharp rerating in the stock as investors responded to better-than-expected revenue and earnings performance. Article Title
• Positive Sentiment: The company said patients were “twice as likely” to choose Novavax’s COVID shot over Moderna’s in a recent comparison, adding to optimism around its vaccine positioning. Article Title
• Positive Sentiment: Unusually large call-option buying suggests traders are positioning for further upside in Novavax (NVAX), with options volume far above normal.
• Neutral Sentiment: Novavax also announced it will participate in the BofA Securities 2026 Health Care Conference, which may give management another venue to update investors on strategy and partnerships. Article Title
• Neutral Sentiment: TD Cowen reiterated a $9 price target, which is supportive but not a major new catalyst. Article Title

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.